Market Research Logo

Europe Lung Cancer Therapeutics Market – Industry Trends and Forecast to 2026

Europe Lung Cancer Therapeutics Market – Industry Trends and Forecast to 2026

Europe lung cancer therapeutics market is expected to grow at a healthy CAGR of 12.7% in the forecast period of 2019 to 2026. The new market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.
Market Segmentation
By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumors, Mediastinal Tumors, Mesothelioma, Chest Wall Tumors), Molecule Type (Small Molecules, Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors, Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), Therapy Type (Single Drug Therapy, Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, Others), Country (U.K., Germany, Spain, France, Italy, Netherlands, Switzerland, Turkey, Belgium, Russia, Rest of Europe) Industry Trends and Forecast to 2026

Major growing sectors under the market segmentation are as follows:

• On the basis of cancer type, the non-small cell lung cancer is dominating the global lung cancer therapeutics market. Lung cancer is the second most common cancer type including small cell and non-small cell lung cancer. Amongst these 80–85% cases are non-small cell lung cancer. This type of cancer grows and spreads more slowly than small cell lung cancer and therefore it is dominating the market.
• On the basis of molecule type, the small molecule segment is dominating the global lung cancer therapeutics market. The small molecule better effects and progression free survival of lung cancer and these agents also inhibit the growth of the metastatic cell. Due to all these reasons they are more preferred than the other types.
• On the drug class, the alkylating drug segment is dominating the lung cancer therapeutics market. This is the first discovered drug for the treatment of cancer. Alkylating directly damage DNA and prevents the cancer cells cell division. The alkylating agent can be used in every stage of cancer. This drug shows pre and post stage. This drug also shows reduced drug accumulation and the increased detoxification.
• On the basis of treatment type, the chemotherapy segment is dominating the lung cancer therapeutics market. Chemotherapy is a traditional process in which drugs are used to kill or inhibit cancerous cells as it is the most accepted treatment. Whereas, targeted therapy is becoming more familiar in the lung cancer sector as these classes of drugs specifically focuses on specific genetic mutations present in the tumor cells.
• On the basis of therapy type, single drug therapy segment is dominating the lung cancer therapeutics market. The single drug therapy is the first evolved therapy used for the treatment of lung cancer. Single drug therapy is dominating the market as it is mostly preferred for the treatment of old age population, patients with poor performance status and patients who are not able to take the combination therapy. Whereas the combination drug therapy is expected to grow in future as many combination drugs are under clinical trials and is expected to launch soon. Also, few studies have shown that combination drugs can have better results as compared to the single drug therapy which will contribute to the growth of the combination therapy in the forecast period.
• On the basis of end user, hospitals segment is dominating the lung cancer therapeutics market. The hospital segment is dominating in the lung cancer therapeutics because hospitals provides many advantages over the other segments which includes, 24hours supportive care, immediate care for the emergency, availability of physicians, surgeons and medication.
• On the basis of distribution channel, hospital pharmacy segment is dominating the lung cancer therapeutics market. Hospital pharmacy is dominating the global lung cancer therapeutics market as the lung cancer therapy products are prescribed based which is majorly available in hospital pharmacy.

Key Market Players

The key market players for Europe lung cancer therapeutics market are listed below:

• Takeda Pharmaceutical Company Limited
• ONO PHARMACEUTICAL CO., LTD.
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Eli Lilly and Company
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Merck & Co., Inc.
• CELGENE CORPORATION
• AMGEN INC.
• Sanofi
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories Ltd.
• ALLERGAN
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Astellas Pharma Inc.
• Sumitomo Dainippon Pharma Co., Ltd.
• Others

The single user license is non-downloadable and non-printable. Global Site license allows these actions.


1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of Europe Lung Cancer Therapeutics Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Currency And Pricing
2.5 Research Methodology
2.6 Primary Interviews With Key Opinion Leaders
2.7 Dbmr Market Position Grid
2.8 Dbmr Market Challenge Matrix
2.9 Dbmr Vendor Share Analysis
2.10 Multivariate Modelling
2.11 Product Time Line
2.12 Secondary Sources
2.13 Assumptions
3 Market Overview
3.1 Drivers
3.1.1 Increasing Cases Of Lung Cancer
3.1.2 Growing Number Of Smokers
3.1.3 Government/Organizations Funding For The R&D Of New Drugs
3.1.4 Increasing Awareness
3.1.5 Strategic Initiatives Of The Companies
3.2 Restrains
3.2.1 Pricing Pressure
3.2.2 High Cost
3.3 Opportunities
3.3.1 Approvals And Product Pipepline
3.3.2 Health Tourism
3.3.3 New Product Launches
3.4 Challenges
3.4.1 Side Effects
3.4.2 Lack Of Number Of Oncologists
3.4.3 Unmet Medical Needs
4 Executive Summary
5 Premium Insights
6 Epidemiology Of Lung Cancer
7 Regulatory Procedure
8 Pipeline Drugs
9 Europe Lung Cancer Therapeutics Market, By Cancer Type
9.1 Overview
9.2 Non-small Cell Lung Cancer
9.2.1 Squamous Cell Carcinoma
9.2.2 Pulmonary Adenocarcinoma
9.2.3 Adenosquamous Carcinoma (Asc)
9.2.4 Large Cell Carcinoma
9.2.5 Sarcomatoid Carcinoma
9.2.6 Undifferentiated Non-small Cell Lung Cancer
9.2.7 Salivary Gland-type Lung Carcinoma
9.2.7.1 Adenoid Cystic Carcinoma
9.2.7.2 Mucoepidermoid Carcinoma
9.2.7.3 Acinic Cell Carcinoma
9.2.7.4 Epithelial-myoepithelial Carcinoma
9.2.7.5 Granular Cell Lung Tumors
9.3 Metastatic Lung Cancer
9.4 Mesothelioma
9.5 Chest Wall Tumors
9.5.1 Primary Tumors
9.5.2 Metastatic Tumors
9.5.3 Sarcomas
9.6 Pulmonary Neuroendocrine Tumors
9.6.1 Carcinoid Tumors
9.6.1.1 Typical Carcinoid Tumors
9.6.1.2 Atypical Carcinoid Tumors
9.6.2 Large Cell Neuroendocrine Lungs Carcinoma
9.6.3 Small-cell Lung Cancer
9.6.3.1 Small Cell Carcinoma
9.6.3.2 Combined Small Cell Carcinoma
9.7 Mediastinal Tumors
9.7.1 Germ Cell Tumors
9.7.2 Lymphomas
9.7.3 Thymomas
10 Europe Lung Cancer Therapeutics Market, By Molecule Type
10.1 Overview
10.2 Small Molecule
10.3 Bilogics
11 Europe Lung Cancer Therapeutics Market, By Drug Class
11.1 Overview
11.2 Alkylating Agents
11.3 Antimetabolites
11.4 Mitotic Inhibitors
11.5 Multikinase Inhibitors
11.6 Egfr Inhibitors
11.7 Others
12 Europe Lung Cancer Therapeutics Market, By Treatment Type
12.1 Overview
12.2 Radiation Therapy
12.2.1 External Beam
12.2.2 Brachytherapy (Internal Or Implant Radiation Therapy)
12.2.3 Stereotactic Body Radiation Therapy (Sbrt) / Stereotactic Ablative Radiotherapy (Sabr)
12.2.4 Stereotactic Radiosurgery (Srs)
12.3 Chemotherapy
12.3.1 Cisplatin
12.3.2 Paclitaxel (Taxol)
12.3.3 Vinorelbine (Navelbine)
12.3.4 Docetaxel (Taxotere)
12.3.5 Alimta
12.3.6 Gemcitabine (Gemzar)
12.3.7 Durvalumab (Imfinzi)
12.3.8 Others
12.4 Targeted Therapy
12.4.1 Epidermal Growth Factor Receptor (Egfr) Inhibitors
12.4.2 Anaplastic Lymphoma Kinase (Alk) Inhibitors
12.4.3 Anti-angiogenesis Therapy
12.4.4 Monoclonal Antibodies
12.4.5 Others
12.5 Immunotherapy
12.5.1 Atezolizumab (Tecentriq)
12.5.2 Durvalumab (Imfinzi)
12.5.3 Nivolumab (Opdivo)
12.5.4 Pembrolizumab (Keytruda)
12.6 Others
13 Europe Lung Cancer Therapeutics Market, By Therapy Type
13.1 Overview
13.2 Single Drug Therapy
13.3 Combination Therapy
14 Europe Lung Cancer Therapeutics Market, By End User
14.1 Overview
14.2 Hospitals
14.3 Specialty Clinics
14.4 Homecare
14.5 Others
15 Europe Lung Cancer Therapeutics Market, By Distribution Channel
15.1 Overview
15.2 Hospital Pharmacy
15.3 Retail Pharmacy
15.4 Online
15.5 Others
16 Europe Lung Cancer Therapeutics Market, By Geography
16.1 Europe
16.1.1 Germany
16.1.2 France
16.1.3 U.K.
16.1.4 Italy
16.1.5 Spain
16.1.6 Switzerland
16.1.7 Netherlands
16.1.8 Belgium
16.1.9 Russia
16.1.10 Turkey
16.1.11 Rest Of Europe
17 Europe Lung Cancer Therapeutics Market, Company Landscape
17.1 Company Share Analysis: Europe
18 Company Profiles
18.1 F. Hoffmann-la Roche Ltd
18.1.1 Company Snapshot
18.1.2 Revenue Analysis
18.1.3 Geographical Presence
18.1.4 Company Share Analysis
18.1.5 Product Portfolio
18.1.6 Recent Developments
18.2 Merck & Co., Inc.
18.2.1 Company Overview
18.2.2 Revenue Analysis
18.2.3 Geographical Presence
18.2.4 Company Share Analysis
18.2.5 Product Portfolio
18.2.6 Recent Developments
18.3 Bristol-myers Squibb Company
18.3.1 Company Overview
18.3.2 Revenue Analysis
18.3.3 Geographical Presence
18.3.4 Company Share Analysis
18.3.5 Product Portfolio
18.3.6 Recent Developments
18.4 Astrazeneca
18.4.1 Company Snapshot
18.4.2 Revenue Analysis
18.4.3 Geographical Presence
18.4.4 Company Share Analysis
18.4.5 Product Portfolio
18.4.6 Recent Developments
18.5 Eli Lilly And Company
18.5.1 Company Snapshot
18.5.2 Revenue Analysis
18.5.3 Geographical Presence
18.5.4 Company Share Analysis
18.5.5 Product Portfolio
18.5.6 Recent Developments
18.6 Allergan
18.6.1 Company Overview
18.6.2 Revenue Analysis
18.6.3 Geographical Presence
18.6.4 Product Portfolio
18.6.5 Recent Developments
18.7 Amgen Inc.
18.7.1 Company Overview
18.7.2 Revenue Analysis
18.7.3 Geographical Presence
18.7.4 Product Portfolio
18.7.5 Recent Developments
18.8 Astellas Pharma Inc.
18.8.1 Company Overview
18.8.2 Revenue Analysis
18.8.3 Geographical Presence
18.8.4 Product Portfolio
18.8.5 Recent Developments
18.9 Boehringer Ingelheim International Gmbh
18.9.1 Company Overview
18.9.2 Revenue Analysis
18.9.3 Geographical Presence
18.9.4 Product Portfolio
18.9.5 Recent Developments
18.10 Celgene Corporation
18.10.1 Company Overview
18.10.2 Revenue Analysis
18.10.3 Geographical Presence
18.10.4 Product Portfolio
18.10.5 Recent Developments
18.11 Dr. Reddy’s Laboratories Ltd.
18.11.1 Company Snapshot
18.11.2 Revenue Analysis
18.11.3 Geographical Presence
18.11.4 Product Portfolio
18.11.5 Recent Developments
18.12 Glaxosmithkline Plc.
18.12.1 Company Overview
18.12.2 Revenue Analysis
18.12.3 Geographical Presence
18.12.4 Product Portfolio
18.12.5 Recent Developments
18.13 Johnson & Johnson Services, Inc.
18.13.1 Company Snapshot
18.13.2 Revenue Analysis
18.13.3 Geographical Presence
18.13.4 Product Portfolio
18.13.5 Recent Developments
18.14 Novartis Ag
18.14.1 Company Snapshot
18.14.2 Revenue Analysis
18.14.3 Geographical Presence
18.14.4 Product Portfolio
18.14.5 Recent Development
18.15 Ono Pharmaceutical Co., Ltd.
18.15.1 Company Overview
18.15.2 Revenue Analysis
18.15.3 Geographical Presence
18.15.4 Product Portfolio
18.15.5 Recent Developments
18.16 Pfizer Inc.
18.16.1 Company Snapshot
18.16.2 Recent Financials
18.16.3 Geographical Presence
18.16.4 Product Portfolio
18.16.5 Recent Developments
18.17 Sanofi
18.17.1 Company Overview
18.17.2 Revenue Analysis
18.17.3 Geographical Presence
18.17.4 Product Portfolio
18.17.5 Recent Developments
18.18 Sumitomo Dainippon Pharma Co., Ltd.
18.18.1 Company Overview
18.18.2 Revenue Analysis
18.18.3 Geographical Presence
18.18.4 Product Portfolio
18.18.5 Recent Developments
18.19 Sun Pharmaceutical Industries Ltd.
18.19.1 Company Snapshot
18.19.2 Revenue Analysis
18.19.3 Geographical Presence
18.19.4 Product Portfolio
18.19.5 Recent Developments
18.20 Takeda Pharmaceutical Company Limited
18.20.1 Company Overview
18.20.2 Revenue Analysis
18.20.3 Geographical Presence
18.20.4 Product Portfolio
18.20.5 Recent Developments
18.21 Teva Pharmaceutical Industries Ltd.
18.21.1 Company Overview
18.21.2 Revenue Analysis
18.21.3 Geographical Presence
18.21.4 Product Portfolio
18.21.5 Recent Developments
19 Questionnaire
20 Related Reports
List Of Tables
Table 1 Prevalence Of Subtypes Of Lung Carcinoma In Smokers And Never-smokers
Table 2 Cost Of Targeted Therapies For The Treatment Of Nsclc (2018)
Table 3 Cost Of Immunotherapies For The Treatment Of Nsclc (2018)
Table 4 Some Of The Pipeline Lung Cancer Drugs Are Mentioned In The Below Table:
Table 5 Average Cost Of Lung Cancer Treatment (2018)
Table 6 Europe Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 7 Europe Non-small Cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 8 Europe Non-small Cell Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 9 Europe Salivary Gland-type Lung Carcinoma In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 10 Europe Metastatic Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 11 Europe Mediastinal Tumors In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 12 Europe Chest Wall Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 13 Europe Chest Wall Tumors In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 14 Europe Pulmonary Neuroendocrine Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 15 Europe Pulmonary Neuroendocrine Tumors In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 16 Europe Carcinoid Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 17 Europe Small-cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 18 Europe Mediastinal Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 19 Europe Mesothelioma In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 20 Europe Lung Cancer Therapeutics Market, By Molecule Type, 2017-2026 (Usd Million)
Table 21 Europe Small Molecule In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 22 Europe Biologics In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 23 Europe Lung Cancer Therapeutics Market, By Drug Class, 2017-2026 (Usd Million)
Table 24 Europe Alkylating Agents In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 25 Europe Antimetabolites In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 26 Europe Mitotic Inhibitors Products In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 27 Europe Multikinase Inhibitors In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 28 Europe Egfr Inhibitors In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 29 Europe Others In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 30 Europe Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 31 Europe Radiation Therapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 32 Europe Radiation Therapy In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 33 Europe Chemotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 34 Europe Chemotherapy In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 35 Europe Targeted Therapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 36 Europe Targeted Therapy In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 37 Europe Immunotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 38 Europe Immunotherapy In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 39 Europe Others In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 40 Europe Lung Cancer Therapeutics Market, By Therapy Type, 2017-2026 (Usd Million)
Table 41 Europe Single Drug Therapy In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 42 Europe Combination Drug Therapy In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 43 Europe Lung Cancer Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 44 Europe Hospitals In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 45 Europe Specialty Clinics In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 46 Europe Homecare In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 47 Europe Others In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 48 Europe Lung Cancer Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 49 Europe Hospital Pharmacy In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 50 Europe Retail Pharmacy In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 51 Europe Online In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 52 Europe Others In Lung Cancer Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 53 Europe Lung Cancer Therapeutics Market, By Country, 2017-2026 (Usd Million)
Table 54 Europe Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 55 Europe Non-small Cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 56 Europe Salivary Gland-type Lung Carcinoma In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 57 Europe Chest Wall Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 58 Europe Pulmonary Neuroendocrine Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 59 Europe Small-cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 60 Europe Carcinoid Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 61 Europe Mediastinal Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 62 Europe Lung Cancer Therapeutics Market, By Molecule Type, 2017-2026 (Usd Million)
Table 63 Europe Lung Cancer Therapeutics Market, By Drug Class, 2017-2026 (Usd Million)
Table 64 Europe Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 65 Europe Chemotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 66 Europe Radiotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 67 Europe Targeted Therapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 68 Europe Immunotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 69 Europe Lung Cancer Therapeutics Market, By Therapy Type, 2017-2026 (Usd Million)
Table 70 Europe Lung Cancer Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 71 Europe Lung Cancer Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 72 Germany Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 73 Germany Non-small Cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 74 Germany Salivary Gland-type Lung Carcinoma In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 75 Germany Chest Wall Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 76 Germany Pulmonary Neuroendocrine Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 77 Germany Small-cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 78 Germany Carcinoid Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 79 Germany Mediastinal Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 80 Germany Lung Cancer Therapeutics Market, By Molecule Type, 2017-2026 (Usd Million)
Table 81 Germany Lung Cancer Therapeutics Market, By Drug Class, 2017-2026 (Usd Million)
Table 82 Germany Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 83 Germany Chemotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 84 Germany Radiotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 85 Germany Targeted Therapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 86 Germany Immunotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 87 Germany Lung Cancer Therapeutics Market, By Therapy Type, 2017-2026 (Usd Million)
Table 88 Germany Lung Cancer Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 89 Germany Lung Cancer Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 90 France Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 91 France Non-small Cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 92 France Salivary Gland-type Lung Carcinoma In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 93 France Chest Wall Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 94 France Pulmonary Neuroendocrine Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 95 France Small-cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 96 France Carcinoid Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 97 France Mediastinal Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 98 France Lung Cancer Therapeutics Market, By Molecule Type, 2017-2026 (Usd Million)
Table 99 France Lung Cancer Therapeutics Market, By Drug Class, 2017-2026 (Usd Million)
Table 100 France Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 101 France Chemotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 102 France Radiotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 103 France Targeted Therapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 104 France Immunotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 105 France Lung Cancer Therapeutics Market, By Therapy Type, 2017-2026 (Usd Million)
Table 106 France Lung Cancer Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 107 France Lung Cancer Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 108 U.K. Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 109 U.K. Non-small Cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 110 U.K. Salivary Gland-type Lung Carcinoma In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 111 U.K. Chest Wall Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 112 U.K. Pulmonary Neuroendocrine Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 113 U.K. Small-cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 114 U.K. Carcinoid Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 115 U.K. Mediastinal Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 116 U.K. Lung Cancer Therapeutics Market, By Molecule Type, 2017-2026 (Usd Million)
Table 117 U.K. Lung Cancer Therapeutics Market, By Drug Class, 2017-2026 (Usd Million)
Table 118 U.K. Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 119 U.K. Chemotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 120 U.K. Radiotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 121 U.K. Targeted Therapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 122 U.K. Immunotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 123 U.K. Lung Cancer Therapeutics Market, By Therapy Type, 2017-2026 (Usd Million)
Table 124 U.K. Lung Cancer Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 125 U.K. Lung Cancer Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 126 Italy Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 127 Italy Non-small Cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type , 2017-2026 (Usd Million)
Table 128 Italy Salivary Gland-type Lung Carcinoma In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 129 Italy Chest Wall Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 130 Italy Pulmonary Neuroendocrine Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 131 Italy Small-cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 132 Italy Carcinoid Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 133 Italy Mediastinal Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 134 Italy Lung Cancer Therapeutics Market, By Molecule Type, 2017-2026 (Usd Million)
Table 135 Italy Lung Cancer Therapeutics Market, By Drug Class, 2017-2026 (Usd Million)
Table 136 Italy Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 137 Italy Chemotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 138 Italy Radiotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 139 Italy Targeted Therapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 140 Italy Immunotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 141 Italy Lung Cancer Therapeutics Market, By Therapy Type, 2017-2026 (Usd Million)
Table 142 Italy Lung Cancer Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 143 Italy Lung Cancer Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 144 Spain Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 145 Spain Non-small Cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 146 Spain Salivary Gland-type Lung Carcinoma In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 147 Spain Chest Wall Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 148 Spain Pulmonary Neuroendocrine Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 149 Spain Small-cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 150 Spain Carcinoid Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 151 Spain Mediastinal Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 152 Spain Lung Cancer Therapeutics Market, By Molecule Type, 2017-2026 (Usd Million)
Table 153 Spain Lung Cancer Therapeutics Market, By Drug Class, 2017-2026 (Usd Million)
Table 154 Spain Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 155 Spain Chemotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 156 Spain Radiotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 157 Spain Targeted Therapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 158 Spain Immunotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 159 Spain Lung Cancer Therapeutics Market, By Therapy Type, 2017-2026 (Usd Million)
Table 160 Spain Lung Cancer Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 161 Spain Lung Cancer Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 162 Switzerland Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 163 Switzerland Non-small Cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type , 2017-2026 (Usd Million)
Table 164 Switzerland Salivary Gland-type Lung Carcinoma In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 165 Switzerland Chest Wall Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 166 Switzerland Pulmonary Neuroendocrine Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 167 Switzerland Small-cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 168 Switzerland Carcinoid Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 169 Switzerland Mediastinal Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 170 Switzerland Lung Cancer Therapeutics Market, By Molecule Type, 2017-2026 (Usd Million)
Table 171 Switzerland Lung Cancer Therapeutics Market, By Drug Class, 2017-2026 (Usd Million)
Table 172 Switzerland Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 173 Switzerland Chemotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 174 Switzerland Radiotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 175 Switzerland Targeted Therapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 176 Switzerland Immunotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 177 Switzerland Lung Cancer Therapeutics Market, By Therapy Type, 2017-2026 (Usd Million)
Table 178 Switzerland Lung Cancer Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 179 Switzerland Lung Cancer Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 180 Netherlands Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 181 Netherlands Non-small Cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type , 2017-2026 (Usd Million)
Table 182 Netherlands Salivary Gland-type Lung Carcinoma In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 183 Netherlands Chest Wall Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 184 Netherlands Pulmonary Neuroendocrine Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 185 Netherlands Small-cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 186 Netherlands Carcinoid Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 187 Netherlands Mediastinal Tumors In Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 188 Netherlands Lung Cancer Therapeutics Market, By Molecule Type, 2017-2026 (Usd Million)
Table 189 Netherlands Lung Cancer Therapeutics Market, By Drug Class, 2017-2026 (Usd Million)
Table 190 Netherlands Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 191 Netherlands Chemotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 192 Netherlands Radiotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 193 Netherlands Targeted Therapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 194 Netherlands Immunotherapy In Lung Cancer Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 195 Netherlands Lung Cancer Therapeutics Market, By Therapy Type, 2017-2026 (Usd Million)
Table 196 Netherlands Lung Cancer Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 197 Netherlands Lung Cancer Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 198 Belgium Lung Cancer Therapeutics Market, By Cancer Type, 2017-2026 (Usd Million)
Table 199 Belgium Non-small Cell Lung Cancer In Lung Cancer Therapeutics Market, By Cancer Type , 2017-2026 (Usd Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report